Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways by Baran, K et al.
Baran	  et	  al.:	  Chronic	  central	  melanocortin-­‐4	  receptor	  antagonism	  and	  central	  neuropeptide-­‐Y	  infusion	  in	  rats	  produce	  increased	  adiposity	  by	  divergent	  pathways	  
Diabetes	  51(1):	  152-­‐158,	  2002	  
 
Chronic central melanocortin-4 receptor antagonism and 
central neuropeptide-Y infusion in rats produce increased 
adiposity by divergent pathways. 
 
Baran K, Preston E, Wilks D, Cooney GJ, Kraegen EW, Sainsbury A 
 
Katherine Baran, From the Diabetes Research Group, the Garvan Institute of Medical Research, Sydney, Australia.; 
Elaine Preston, From the Diabetes Research Group, the Garvan Institute of Medical Research, Sydney, Australia.; 
Donna Wilks, From the Diabetes Research Group, the Garvan Institute of Medical Research, Sydney, Australia.; 
Gregory J. Cooney, From the Diabetes Research Group, the Garvan Institute of Medical Research, Sydney, 
Australia.; Edward W. Kraegen, From the Diabetes Research Group, the Garvan Institute of Medical Research, 
Sydney, Australia. and Amanda Sainsbury, From the Diabetes Research Group, the Garvan Institute of Medical 
Research, Sydney, Australia. 
 
Increased hypothalamic neuropeptide-Y (NPY) action and disruption of the melanocortin 
(MC)-4 receptor both result in hyperphagia and obesity. To determine whether similar 
hormonal and metabolic mechanisms are involved in these two obesity syndromes, we 
investigated the time course of effects induced by 6-day intracerebroventricular (ICV) infusion 
of NPY (3.5 nmol/day) or the MC4 receptor antagonist HS014 (4.8 nmol/day) in rats pair-fed 
with vehicle-infused controls. The weight of white adipose tissue (WAT) deposits was 
increased after 6-day NPY and HS014 infusion compared with controls, and the increase was 
significantly greater in HS014- than in NPY-infused rats (retroperitoneal WAT: NPY 0.57 ± 
0.05; HS014 0.80 ± 0.05; control 0.43 ± 0.03% body wt, n = 8 - 13, P < 0.05). Plasma leptin 
was also increased in both experimental groups (NPY 10.6 ± 1.9; HS014 4.4 ± 0.9; control 2.0 
± 0.1 ng/ml, n = 8 - 13, P < 0.05 for all comparisons). Basal plasma corticosterone and insulin 
levels were increased by ICV NPY infusion, whereas HS014-infused rats showed no 
significant increase in these parameters on any of 1–6 days of infusion. Both NPY and HS014 
infusion potentiated intravenous glucose-induced (300 mg/kg) plasma insulin levels, and there 
was no difference in glycemia among groups. In NPY-infused rats, the plasma free fatty acid 
levels were decreased and triglyceridemia was increased compared with controls, but these 
parameters were unchanged in HS014-infused rats. Hepatic triglyceride content was 
significantly increased by HS014 but not by NPY infusion. Levels of uncoupling protein-1 
mRNA in brown adipose tissue were significantly decreased after 6 days of HS014 infusion, 
similar to the effect of central NPY. Because ICV HS014 induced at least as great an increase 
in fat mass as ICV NPY and yet had divergent hormonal and metabolic effects, we conclude 
that MC4 receptor antagonism does not induce obesity solely by regulation of the 
endogenous NPY-ergic system. 
 
Abbreviations:	  	  AgRP,	  agouti-­‐related	  protein;	  BAT,	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  free	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  acid;	  GAPDH,	  
glyceraldehyde	  3-­‐phosphate	  dehydrogenase;	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  intracerebroventricular,	  MC,	  melanocortin;	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  nucleus;	  TG,	  triglyceride;	  UCP-­‐1,	  
uncoupling	  protein-­‐I;	  WAT,	  white	  adipose	  tissue. 
 
 
  Neuropeptide-Y (NPY) is a highly potent orexigenic peptide synthesized in the brain (1). 
Genetically obese ob/ob and db/db mice and fa/fa rats exhibit a lack of leptin function as their 
primary defect (2–5), and all exhibit increased NPY expression and secretion in the 
hypothalamus (6) caused by a lack of leptin's known inhibitory effect on NPY-ergic activity (7). 
Although other peptides are likely to be involved (1), this increase in hypothalamic NPY 
probably contributes to obesity in ob/ob, db/db, and fa/fa rodents because 
intracerebroventricular (ICV) infusions of NPY in normal rodents produce effects similar to 
those seen in the genetically obese rodent models. These include increased food intake, body 
weight, fat accumulation, plasma insulin, leptin, and corticosterone concentrations, decreased 
brown adipose tissue (BAT) thermogenesis, and inhibition of the somatotropic and 
gonadotropic axes (8–12). 
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  Several dominant mutations at the agouti locus in the mouse also cause a syndrome of 
marked obesity, hyperinsulinemia, insulin resistance, and hyperglycemia (13–15). 
Antagonism of the hypothalamic melanocortin (MC)-4 receptor by ectopically expressed 
agouti is probably the cause of the agouti mouse obesity syndrome (16), because MC4 
receptor knockout mice have an obesity syndrome identical to that of the agouti obese mouse 
(17). Agouti-related protein (AgRP), a high affinity endogenous antagonist of the MC3 and 
MC4 receptor (18,19), is probably involved in energy homeostasis, because hypothalamic 
AgRP expression is increased in fasting rats (20,21), and ICV AgRP infusions stimulate food 
intake in both starved and satiated rats (22,23). So far, little is known about the mechanisms 
and primary etiological causes of obesity in agouti mice and MC4 receptor knockout mice. 
Studies involving central administration of exogenous MC4 receptor antagonists have focused 
primarily on effects of feeding, and little is known about the effect that chronic MC4 receptor 
antagonism has on the peripheral hormonal and metabolic parameters known to alter energy 
homeostasis or the time-course of these effects. Long-term administration of the MC4 
receptor antagonist HS014 has been reported to increase food intake and consequently 
increase body weight and adiposity (24). Additionally, chronic administration of the MC4 
receptor antagonist SHU911 in rats allowed to eat ad libitum resulted in increased food 
intake, adiposity, plasma corticosterone, insulin, and leptin, with no changes in plasma growth 
hormone, insulin-like growth factor-1, leutenizing hormone, follicle-stimulating hormone, and 
testosterone (25). These observed effects could be a result of increased food intake, and 
currently no studies have observed the sequential hormonal and metabolic effects after 
chronic MC4 receptor antagonism in rats where increased food intake is prevented. 
 
  There is some evidence that the mechanisms contributing to obesity in genetically obese 
ob/ob and fa/fa rodents (which exhibit early onset obesity, early onset hyperinsulinemia, 
decreased linear growth, and elevated levels of plasma corticosterone) are in some ways 
different to the etiology of obesity in agouti and MC4 receptor knockout mice (which exhibit 
late-onset obesity, late-onset hyperinsulinemia, increased linear growth, and no effects on 
basal plasma corticosterone levels) (13,14). On the contrary, other available evidence 
suggests that chronic central MC4 receptor antagonism induces obesity at least partially via 
the NPY-ergic system (26). Agouti obese mice exhibit increased levels of NPY mRNA in the 
dorsomedial nucleus (27). Furthermore, the orexigenic effects of the specific MC4 receptor 
antagonist HS014 were partially inhibited by an NPY-Y1 receptor antagonist (28) and 
completely blocked by fluoxetine, which inhibits NPY release (29,30). Therefore, the available 
literature provides conflicting evidence as to whether MC4 receptor antagonism induces 
obesity and any hormonal and metabolic changes via actions on the endogenous NPY-ergic 
system. 
 
  To determine whether similar pathways are involved in the obesity syndromes induced by 
chronic central NPY-ergic activation and chronic MC4 receptor antagonism, we compared the 
hormonal and metabolic effects of 6-day ICV NPY or MC4 receptor antagonist (HS014) 
infusion in normal rats. All rats were pair-fed with vehicle-infused controls in order to study the 
effects of NPY and HS014 in the absence of their known hyperphagic effects (8,28). 
 
 
RESEARCH DESIGN AND METHODS 
Experimental animals. All procedures were approved by the Animal Experimentation Ethics 
Committee of the Garvan Institute/St Vincent's Hospital and are in keeping with the National 
Health and Medical Research Council of Australia's guidelines on animal experimentation. 
Male Wistar rats were purchased from Animal Resources Center (Perth, Australia) at weights 
of 250–280 g. They were housed in groups in plastic cages on pellet paper bedding and 
under conditions of controlled temperature (23°C) and illumination (0600–1800). They were 
allowed ad libitum access to standard laboratory diet (Norco Stockfeeds, South Lismore, 
Australia) and water, unless otherwise stated. 
Placement of chronic ICV and Jugular cannulae. Animals were anesthetized with an 
intraperitoneal injection of ketamine and xylazine at 60 and 10 mg/kg, respectively (Mavlab, 
Brisbane, Australia, and Troy Laboratories, Sydney, Australia, respectively), for the placement  
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of a cannula in the right lateral cerebral ventricle (11), which was used for all ICV 
administrations. Another cannula was placed in the right jugular vein for blood sampling. Rats 
received an intramuscular injection of penicillin at 0.3 mg/kg (Troy Laboratories) as well as a 
subcutaneous analgesic, buprenorphine (Temgesic 0.025 mg/kg) (Reckitt and Coleman, Hull, 
U.K.), and were left to recover to presurgery weights (7–10 days) in individual cages, with 
daily handling to minimize stress. 
Acute ICY injection of NPY and HS014. A subset of rats were used in acute (4-h) feeding 
studies after bolus ICV injection of porcine NPY (1.2 nmol) (Auspep, Melbourne, Australia), 
synthetic MC4 receptor antagonist HS014 (1.5 nmol) (Auspep), or vehicle (5 μl of 0.9% NaCl) 
for control rats. Injections were made over a period of 60 s, animals were then returned to 
their cages, and total ad libitum food intake was measured after 4 h. 
Chronic ICV infusion of NPY and HS014. Rats were anesthetized with halothane 
(Veterinary Companies of Australia, Sydney, Australia) for implantation of subcutaneous 
osmotic minipumps (model 2001; Alza, Palo Alto, CA) (11), which were connected via 
polyethylene tubing to the ICV cannula for central infusion of porcine NPY (3.5 nmol/day), 
HS014 (4.8 nmol/day), or vehicle (24 μl/day of 0.9% NaCl) for control rats. Food intake of the 
NPY- and HS014-infused rats was restricted to that of the vehicle-infused animals (30–32 
g/day) to ensure that any differences observed were not caused by increased food intake. 
Rats were fasted for 2–3 h (from ∼0930 to 1230). Basal blood samples (0.3 ml) were collected 
dally from the jugular cannula between 1130 and 1230 each day using sodium citrate (6.1 
mg/ml in 0.9% NaCl) as an anticoagulant. Then, 3–4 days after minipump implantation, an 
intravenous glucose tolerance test was performed where blood samples were taken 1 and 5 
min after intravenous glucose injection (300 mg/kg). These two time points were chosen 
because we have previously shown that insulinemia attains a peak at 1 min after such 
glucose injection and returns toward baseline values within 5 min (31). Incremental areas 
under the resultant insulin curves were calculated Coy subtracting baseline values) between 0 
and 5 min after glucose injection. All plasma samples were frozen in liquid N&sub2; and 
stored at -20°C until analysis. Plasma concentrations of triglyceride (TG) (Sigma Diagnostics, 
St. Louis, MO), nonesterified fatty acid (Wako, Osaka, Japan), and glucose (glucose oxidase 
method; Trace Scientific, Melbourne, Australia) were measured using commercial kits. 
Plasma corticosterone and leptin, basal, and glucose-stimulated insulin levels were measured 
by radioimmunoassay kits (ICN Biomedicals, Costa Mesa, CA, and Linco Research, St. Louis, 
MO, respectively). 
Tissue collection from NPY- and HS014-infused rats. After 5–6 days of minipump infusion, 
rats were anesthetized with halothane, the interscapular BAT and liver were then removed 
and weighed, and portions were freeze-clamped and stored at -80°C until analysis. 
Epididymal and retroperitoneal fat pads were then excised and weighed. 
BAT uncoupling protein-1 mRNA analysis. Total RNA was extracted from BAT samples 
using TRI-Reagent (Sigma) according to the manufacturer's instructions. The mouse 
uncoupling protein-1 (UCP-1) probe was generated by polymerase chain reaction from 
genomic DNA. The 182-bp long fragment corresponding to exon 3 was labeled with [α-
32P]dCTP, using a megaprime DNA labeling kit (Amersham, Buckinghamshire, England), and 
Northern blot analysis was carried out under standard conditions. Blots were washed under 
stringent conditions before autoradiographic exposure to Kodak BioMax film at -80°C for 2–3 
days. As a control for loading, the same blot was hybridized with glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) probe, and all ratios of UCP-1—to—GAPDH optical density were 
expressed as a percentage of control values. All films were analyzed with a computer-
assisted image analysis system connected to a GS-690 Imaging Densitometer (Bio-Rad, 
Hercules, CA). 
Liver analysis. Liver samples (50 mg) were homogenized in a glass hand-held homogenizer 
in a 4-ml chloroform:methanol (2:1) solution, and lipids were left to extract into the organic 
phase for 12–16 h at room temperature. Two milliliters of 0.6% NaCl solution was added, and 
then the tubes were vortexed and centrifuged for 10 rain at 4°C (825g). The lower organic 
phase containing lipids was transferred to glass scintillation vials and dried under nitrogen 
gas. The dried lipids were then resuspended in 500 μl ethanol and stored at -20°C until a TG 
assay was performed (Peridochrome TG kit; Roche Diagnostics). Statistics. Statistics were 
performed using Statview version 4.5 (Abacus Concepts). Repeated measures or factorial 
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analysis of variance tests were used for the statistical analysis of results, with Fisher's post 
hoc tests where appropriate. Data are expressed as means ± SD, and the results were 
considered statistically significant at P < 0.05. 
 
RESULTS 
Dose of NPY and HS014. To standardize the biological potency of NPY and HS014, we 
chose doses of these compounds that produce similar and maximal degrees of hyperphagia 
in ad libitum—fed rats. After acute ICV injection of a maximum dose of NPY (1.2 nmol) (32), 
rats consumed sevenfold as much diet as vehicle-injected rats in the ensuing 4 h (Fig. 1). A 
similar 4-h food intake was obtained after ICY injection of 1.5 nmol of HS014 (Fig. 1), and 
higher doses did not produce greater hyperphagia (data not shown). For chronic infusion 
studies, three times this maximally effective acute dose was infused over each 24-h period as 
previously described for NPY (11). Because all animals were fed the same amount as 
vehicle-infused controls during chronic infusions, latency to feed was used as an index of 
biological potency of NPY and HS014. In both NPY- and HS014-infued rats, latency to feed 
was <30 s on each of days 2–6 of infusion compared with >60 s in vehicle-infused controls 
(data not shown). If the latency to feed was >30 s, animals were excluded from the NPY- or 
HS014-infused groups (<10% of rats). 
 
 
 
Body weight and adiposity of NPY- and HS014- infused rats. There was no significant 
difference among NPY-, HS014-, and saline-infused rats with respect to body weight before 
infusion (NPY 354 ± 8, HS014 372 ± 7, and control 367 ± 6 g, n = 9 - 16, NS) or with respect 
to body weight gain during the 6 days of infusion (Fig. 2A). This is consistent with data 
showing that whereas chronic ICV NPY or MC4 receptor antagonist infusion significantly 
increases body weight in ad libitum—fed rats (8,24,25,33), no such increase is observed 
when hyperphagia is prevented by pair-feeding with vehicle-infused controls (11,33,34). 
However, 6 days of central infusion of NPY or HS014 with pair-feeding to control rats 
significantly increased fat accumulation in the epididymal and retroperitoneal white adipose 
tissue (WAT) depots compared with saline-infused controls (Fig. 2B). Furthermore, the 
retroperitoneal fat depot weight was significantly greater in HS014-infused than in NPY-
infused rats (Fig. 2B). The 6 days of ICV infusion of both NPY and HS014 resulted in 
significant increases in plasma leptin levels compared with controls, but the effect was 
significantly greater in NPY-infused rats than in rats infused with HS014 (Fig. 2C). 
Plasma corticosterone, insulin, and glucose levels during chronic ICV NPY or HS014 
infusions. The plasma concentrations of corticosterone during the 6 days of ICV infusion are 
shown in Fig. 3A. Compared with the vehicle-infused control rats, pair-fed NPY-infused rats 
had an increase in plasma corticosterone levels during the first 2 days of infusion. In contrast, 
long-term ICV infusion of the MC4 receptor antagonist HS014 with pair-feeding to control rats 
had no significant effect on corticosteronemia at any time point. NPY-infused rats exhibited  
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significantly greater plasma insulin levels compared with control and HS014-infused rats over 
the 6 days of central infusion (Fig. 3B). Rats chronically ICV-infused with HS014 exhibited no 
significant difference from control values in plasma insulin levels over the 6 days of infusion 
(Fig. 3B). Levels of glycemia were not significantly changed from control values in ICV NPY- 
or HS014-infused rats (Fig. 3C). 
 
 
 
Plasma insulin and glucose levels after intravenous glucose injection. Immediately 
before glucose injection, basal insulinemia was greater than control values in NPY- but not 
HS014-infused rats (Fig. 4A). Intravenous glucose-induced plasma insulin levels were more 
elevated than control values for both NPY- and HS014-infused rats at 1 and 5 rain 
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postglucose injection (Fig. 4A), and the difference was significant at 5 min. The incremental 
areas under the insulin curves shown in Fig. 4 are NPY 3,960 ± 440, P = 0.08 vs. control; 
HS014 5,130 ± 330, P < 0.001 vs. control; and control 2,750 ± 470 pmol/1 × 5 min, with no 
significant difference between NPY- and HS014-infused rats. Plasma glucose levels of NPY- 
and HS014-infused rats were no different from control values either before or at any time after 
glucose injection (Fig. 4B). 
 
 
Plasma lipid concentrations during chronic ICV NPY or HS014 infusion. The plasma 
concentrations of free fatty acids (FFAs) and TGs are shown in Fig. 5. Plasma FFA levels in 
NPY-infused rats were significantly reduced compared with saline and HS014-infused rats for 
the first 3 days of ICV infusion (Fig. 5A). Plasma FFA levels in HS014-infused rats were not 
significantly different from control levels for the entire 6 days of infusion (Fig. 5A). Plasma TG 
levels of NPY-infused rats were significantly elevated compared with control and HS014-
infused rats on days 1–5 of central infusion (Fig. 5B). Plasma TG levels of HS014-infused rats 
were not significantly different relative to controls during the infusion period (Fig. 5B). 
Baran	  et	  al.:	  Chronic	  central	  melanocortin-­‐4	  receptor	  antagonism	  and	  central	  neuropeptide-­‐Y	  infusion	  in	  rats	  produce	  increased	  adiposity	  by	  divergent	  pathways	  
Diabetes	  51(1):	  152-­‐158,	  2002	  
 
Liver TG content after chronic ICV NPY or HS014 infusion. Hepatic TG content was 
significantly increased over control values in HS014- but not NPY-infused rats (Fig. 5C). 
There was no significant difference among the three groups with respect to liver weight after  
 
5–6 days of infusion (NPY 13.2 ± 0.3, HS014 12.6 ± 0.5, and control 12.0 ± 0.3 g, n = 4–8, 
NS). 
 
 
BAT weight and UCP-1 mRNA levels after chronic ICV NPY or HS014 infusion. BAT 
weight was significantly increased over control values after 5–6 days of ICV NPY or HS014 
infusion (NPY 0.36 ± 0.05, HS014 0.33 ± 0.02, and control 0.16 ± 0.02 g, n = 5–6, both P < 
0.01 vs. control). Both NPY- and HS014-infused rats exhibited a significantly lower level of 
UCP-1 mRNA in the BAT compared with that of saline-infused controls, with no significant 
difference between the NPY- and HS014-infused groups (Fig. 6). 
 
DISCUSSION 
This work investigated whether aspects of the obesity syndromes induced by chronically 
increased NPY-ergic activity or central MC4 receptor antagonism are mediated by 
independent or common pathways. To this end, we compared the time course of hormono-
metabolic consequences of chronic ICV infusion of NPY and HS014 (an analogue of the 
endogenous MC3/MC4 receptor antagonist AgRP) in rats, where hyperphagia had been 
prevented by pair-feeding. 
  It was demonstrated that 6 days of central infusion of either NPY or HS014 in rats resulted in 
significant increases in WAT mass, even though NPY- and HS014-infused rats were 
prevented from overeating by pair-feeding with vehicle-infused control rats. As with another 
very recent study using 7-day ICV AgRP injections (33), we demonstrated that MC4 receptor 
antagonist-infused rats show an increase in WAT mass in the absence of increased food 
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intake. Our study also extends this observation by making a direct comparison of the effects 
of central HS014 infusion with those of NPY and by time course comparison of endocrine and 
metabolic effects. Because ICV HS014 induced at least as great an increase in fat mass as 
ICV NPY and yet had divergent hormonal and metabolic effects, we conclude that MC4 
receptor antagonism does not induce obesity solely by regulation of the endogenous NPY-
ergic system. 
 
 
Baran	  et	  al.:	  Chronic	  central	  melanocortin-­‐4	  receptor	  antagonism	  and	  central	  neuropeptide-­‐Y	  infusion	  in	  rats	  produce	  increased	  adiposity	  by	  divergent	  pathways	  
Diabetes	  51(1):	  152-­‐158,	  2002	  
 
 
 
 
  Because plasma concentrations of leptin are positively correlated with percent body fat (35), 
increased plasma leptin levels in NPY- and HS014-infused rats probably reflected the 
increased adiposity. However, plasma leptin levels of rats infused with the MC4 receptor 
antagonist HS014 were significantly lower than those of NPY-infused rats, even though 
adiposity in the HS014 group was at least as great. A similar outcome was recently reported 
in comparison of effects of ICV SHU9119 and NPY in ad libitum—fed rats (25). This highlights 
the fact that leptinemia is regulated by many factors besides fat mass (35). Corticosterone 
and insulin, plasma levels of which were shown to be increased in NPY- but not HS014-
infused rats, are both known to positively regulate plasma leptin levels (35). Additionally, other 
researchers have shown that plasma testosterone levels are significantly reduced by NPY but 
not by SHU9119 infusion (12,25), and because testosterone is an inhibitor of leptin secretion 
(35), this difference may also contribute to the lower plasma leptin levels of the HS014 group. 
  It has recently been reported that chronic central infusion of the MC3/MC4 receptor 
antagonist SHU9119 increased plasma corticosterone levels in ad libitum—fed rats (25). This 
effect was probably mediated by SHU9119-induced hyperphagia because feeding is known to 
increase corticosteronemia (36), and because in the present study MC4 receptor antagonist 
infusion with concomitant pair-feeding caused no such hypercorticosteronemia. Our finding is 
in keeping with reports that animal models with chronic MC4 receptor antagonism, such as 
MC4 receptor knockout mice and agouti obese yellow mice, do not have elevated basal 
plasma corticosterone levels (17). 
  High plasma levels of insulin are known to contribute to obesity because attenuation of the 
hyperinsulinemia of genetically obese rodents (37,38) reduced the obese phenotype in the 
absence of significant effects on feeding. Furthermore, administration of exogenous insulin to 
animals and humans results in increased fat accumulation and other metabolic defects 
characteristic of obesity (39–41). NPY-infused rats exhibited two- to threefold increases over 
controls in basal plasma insulin levels over the infusion period. This hyperinsulinemia, in 
addition to reduced thermogenesis (9,42–45), is the likely primary mechanism by which NPY-
infused rats become obese in the absence of hyperphagia. In contrast to the NPY-infused 
group, rats that received HS014 infusions did not exhibit any significant change in insulinemia 
relative to control rats, indicating that hyperinsulinemia may not be the only contributor to the 
observed increase in adiposity. Glucose-stimulated plasma insulin concentrations were 
elevated in both NPY- and HS014-infused rats in the absence of any difference from controls 
in glycemia, an indication of insulin resistance. This increased insulin response to glucose in 
both obesity models may be mediated by insulin resistance, which is commonly observed in 
situations of increased fat mass, as in ICV NPY-infused rats (11). Therefore, the late-onset 
hyperinsulinemia observed in MC4 receptor knockout and agouti obese yellow mice is 
unlikely to result from a primary defect in insulin secretion, and hyperinsulinemia probably 
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develops secondary to insulin resistance. 
  In addition to the hormonal differences discussed above, differences in metabolic profiles 
were also observed between ICV NPY- and MC4 receptor antagonist-induced increases in 
adiposity, suggesting independent etiologies. Whereas central NPY infusion significantly 
reduced plasma FFA and increased plasma TG levels (possibly mediated by 
hyperinsulinemia and/or reduced sympathetic nervous activity), the plasma concentrations of 
FFAs and TGs in HS014-infused rats were not significantly different from controls, reflective 
of the unchanged plasma insulin profile. Unlike NPY-infused rats, the total liver TG content 
observed in rats infused with HS014 was increased relative to controls, despite no change in 
tissue weight. 
  It is well established that central NPY administration decreases sympathetically mediated 
thermogenic activity in BAT (9,42–45), most likely by decreasing the expression of UCP-1 (9). 
This effect is likely to contribute to NPY-induced obesity because BAT ablation per se also 
results in an obesity syndrome (46). This study has shown that UCP-1 mRNA levels are also 
decreased in BAT after 6 days of central MC4 receptor antagonism with HS014, extending a 
recent report that 7-day ICV AgRP injection with pair-feeding decreased the levels of UCP-1 
protein in BAT (33). Furthermore, the extent of BAT UCP-1 mRNA downregulation in HS014-
infused rats was at least as great as that induced by 6-day ICV NPY infusion. Recently, it was 
reported that ICV NPY infusion or antagonism of central MC3 and MC4 receptors with AgRP 
could reduce the plasma levels of thyroid-stimulating hormone and T4 (33,47,48). Reduced 
thyroid function could reduce wholebody energy expenditure and contribute to increased 
energy retention as fat. 
  The heterogeneity of hormonal and metabolic consequences of central NPY infusion or MC4 
receptor antagonism shown in this study are supported by a recent comparison of brain sites 
of c-Fos activation in response to NPY or the MC3/MC4 receptor antagonist AgRP-(83–132) 
(49). c-Fos immunoreactivity was significantly increased over control values in the 
hypothalamic PVN of both NPY- and AgRP-injected rats, measured at 2 h after ICV injection. 
In contrast, only NPY significantly increased c-Fos activation in the NTS at this time point, 
although AgRP did produce a lesser degree of c-Fos activation in this site at 24 h after 
injection. Only AgRP resulted in significantly increased c-Fos immunoreactivity in the 
accumbens shell and the lateral septum (49). The PVN is implicated as a site regulating BAT 
thermogenesis (9) and activity of the thyrotropic axis (48), whereas the NTS is implicated in 
mediation of NPY-induced insulin secretion (50). Collectively, these data fit the hypothesis 
that both NPY and MC receptor antagonism reduce thyroid function (47,48) and BAT UCP-1 
expression by effects on the PVN, yet only NPY has significant effects on basal 
hyperinsulinemia, mediated by neuronal activation in the NTS. 
  In conclusion, the differences in hormonal and metabolic perturbations that develop during 
the early stages of ICV NPY and HS014 infusions, using doses that produce similar increases 
in adiposity, suggest that NPY and MC4 receptor antagonism induce increases in fat mass via 
at least partially divergent pathways. In the NPY obesity model, hypercorticosteronemia and 
hyperinsulinemia are early onset factors. In contrast, the increase in adiposity induced by 
chronic central MC4 receptor antagonism does not appear to involve hypercorticosteronemia 
or basal hyperinsulinemia. However, it is likely that the etiology of both obesity models 
involves increased glucose-induced insulin secretion, possibly secondary to increased fat 
mass and insulin resistance, and downregulation of BAT UCP-1 mRNA expression, which 
may be mediated by changes in thyroid function as recently reported (33,47,48). 
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GRAPH: FIG. 1. Total ad libitum food intake in the 4 h after acute ICV injection of NPY (1.2 
nmol) or HS014 (1.5 nmol) compared with ICV vehicle-injected control rats (5.0 μl of 0.9%  
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NaCl). Plotted values are means ± SD of 4-7 rats per group. **P < 0.01 NPY vs. control; ##P 
< 0.01 HS014 vs. control. 
GRAPH: FIG. 2. Change in body weight (A), WAT weights as a percent of body weight (B), 
and plasma leptin levels (C) measured after 5–6 days of ICV infusion of NPY (3.5 nmol/day) 
or HS014 (4.8 nmol/day) in rats pair-fed with vehicle-infused controls. Plotted values are 
means ± SD of 8–27 rats per group. *P < 0.05 NPY vs. control; #P < 0.05 HS014 vs. control 
group; †P < 0.05 NPY vs. HS014. 
GRAPH: FIG. 3. Plasma levels of corticosterone (A), insulin (B), and glucose (C) measured 
during 6-day ICV infusion of NPY (3.5 nmol/day) or HS014 (4.8 nmol/day) in rats pair-fed with 
vehicle-infused controls. Plotted values are means ± SD of 5–15 rats per group. *P < 0.05 
NPY vs. corresponding control; †P < 0.05 NPY versus corresponding HS014. 
GRAPH: FIG. 4. Plasma levels of insulin (A) and glucose (B) measured at 1 and 5 min after 
an intravenous glucose injection (300 mg/kg) in rats ICV-infused for 3–4 days with NPY (3.5 
nmol/day) or HS014 (4.8 nmol/day) and pair-fed with vehicle-infused controls. Plotted values 
are means ± SD of 4–14 rats per group. *P < 0.05 NPY vs. corresponding control; #P < 0.05 
HS014 vs. corresponding control. 
GRAPH: FIG. 5. Plasma levels of FFAs (A), TGs (B), and hepatic TG content (C) measured 
after 6 days of ICV infusion of NPY (3.5 nmol/day) or HS014 (4.8 nmol/day) in rats pair-fed 
with vehicle-infused controls. Plotted values are means ± SD of 4–15 rats per group. *P < 
0.05 NPY vs. corresponding control; ##P < 0.01 HS014 vs. corresponding control; †P < 0.05 
NPY vs. corresponding HS014. 
GRAPH: FIG. 6. Levels of mRNA for UCP-1 in BAT after 6 days of ICV infusion of NPY (3.5 
nmol/day) or HS014 (4.8 nmol/day) in rats pair-fed with vehicle-infused controls. UCP-1 
mRNA levels were standardized against those of GAPDH, and expressed as a percentage of 
controls. Plotted values are means ± SD of 5–7 rats per group. *P < 0.05 NPY versus 
corresponding control; ##P < 0.01 HS014 vs. corresponding control. 
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